Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330257 | 0.82 | MME (0.41) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL18193322 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL18011825 | 0.81 | ALDH1A1 (0.35) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL14894449 | 0.78 | MAPK1 (0.47) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL19116285 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TDP1ECE1CYP3A4TSHR | |
| SCHEMBL16644774 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL19116169 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TDP1ECE1CYP3A4TSHR | |
| SCHEMBL10199485 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL24245456 | 0.78 | ALDH1A1 (0.33) | ALDH1A1TDP1LMNAMAPTPTGS2 | |
| SCHEMBL19115860 | 0.77 | ALDH1A1 (0.39) | ALDH1A1TDP1MAPTECE1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | ALDH1A1 618/4885TDP1 3390/4885LMNA 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.